Author details

Full Name

Yizhou Dong

Affiliation

ORCID

Career Start Year

2005

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37500773	Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy.		2023
36414195	Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines.	Journal of Controlled Release	2023
37933232	Adoptive cell therapy for cancer treatment.		2023
37647899	Lysosomal cystine governs ferroptosis sensitivity in cancer via cysteine stress response.		2023
37139419	mRNA delivery in cancer immunotherapy.		2023
37321375	Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.		2023
36942873	STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2.		2023
36748274	Cholesterol-Amino-Phosphate (CAP) Derived Lipid Nanoparticles for Delivery of Self-Amplifying RNA and Restoration of Spermatogenesis in Infertile Mice.		2023
37104673	Advances in engineering and delivery strategies for cytokine immunotherapy.		2023
37520399	Deciphering and targeting host factors to counteract SARS-CoV-2 and coronavirus infections: insights from CRISPR approaches.		2023
34933291	Recent advances of biomaterials in stem cell therapies.	Nanotechnology	2022
35879545	Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection.	Nat Chem Biol	2022
35418466	IL-27 Induces CCL5 Production by T Lymphocytes, Which Contributes to Antitumor Activity.	Journal of Immunology	2022
36121735	Nanomaterials-Mediated Co-Stimulation of Toll-Like Receptors and CD40 for Antitumor Immunity.	Advanced Materials	2022
32483657	Formulation and Delivery Technologies for mRNA Vaccines.	Current Topics in Microbiology and Immunology	2022
35301053	Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy.	Journal of Controlled Release	2022
34986508	Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response-dependent destabilization of tumor protein P53.	Hepatology	2022
34979806	Opportunities and Challenges in mRNA Therapeutics.	Accounts of Chemical Research	2022
34767864	Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer.	Advanced Drug Delivery Reviews	2022
34541724	Construction of Messenger RNA (mRNA) Probes Delivered By Lipid Nanoparticles to Visualize Intracellular Protein Expression and Localization at Organelles.	Advanced Materials	2021
34115079	Harnessing lipid nanoparticles for efficient CRISPR delivery.	Biomaterials Science	2021
34279087	Lipids and Lipid Derivatives for RNA Delivery.	Chemical Reviews	2021
33243123	Computational and Experimental Approaches to Investigate Lipid Nanoparticles as Drug and Gene Delivery Systems.	Current Topics in Medicinal Chemistry	2021
34793124	Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.	Accounts of Chemical Research	2021
34394960	Lipid nanoparticles for mRNA delivery.	Nature Reviews Materials	2021
34907171	Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.	Nature Communications	2021
34447945	Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity.	Nature Cancer	2020
31907443	Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis.	Nature Nanotechnology	2020
32119776	Rational Design of Small Molecules to Enhance Genome Editing Efficiency by Selectively Targeting Distinct Functional States of CRISPR-Cas12a.	Bioconjugate Chemistry	2020
32346117	Author Correction: Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis.	Nature Nanotechnology	2020
32045875	CRISPR-Cas12a Possesses Unconventional DNase Activity that Can Be Inactivated by Synthetic Oligonucleotides.	Molecular Therapy - Nucleic Acids	2020
32206737	Long-term storage of lipid-like nanoparticles for mRNA delivery.	Bioactive Materials	2020
31862124	Strategies for the CRISPR-Based Therapeutics.	Trends in Pharmacological Sciences	2020
32875709	Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo.	Advanced Materials	2020
33088681	Recent advances of antibody drug conjugates for clinical applications.	Acta Pharmaceutica Sinica B	2020
32973772	Consequences of CRISPR-Cas9-Mediated CFTR Knockout in Human Macrophages.	Frontiers in Immunology	2020
32511313	Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo.		2020
32937374	Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing.	Science advances	2020
31102606	Strategies, design, and chemistry in siRNA delivery systems.	Advanced Drug Delivery Reviews	2019
31737223	Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer.	Nano Research	2019
31750420	Antibiotic-Derived Lipid Nanoparticles to Treat Intracellular .	ACS Applied Bio Materials	2019
30594452	Design, synthesis and evaluation of anti-CD38 antibody drug conjugate based on Daratumumab and maytansinoid.	Bioorganic and Medicinal Chemistry	2019
29726120	Nanoscale platforms for messenger RNA delivery.	Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology	2019
31005367	Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR).	Bioorganic and Medicinal Chemistry	2019
31255978	RNA delivery biomaterials for the treatment of genetic and rare diseases.	Biomaterials	2019
29622802	Design and assessment of engineered CRISPR-Cpf1 and its use for genome editing.		2018
31737222	Co-delivery of mRNA and SPIONs through amino-ester nanomaterials.	Nano Research	2018
30555598	Lipid Polymer Hybrid Nanomaterials for mRNA Delivery.	Cellular and Molecular Bioengineering	2018
30542568	Ratiometric fluorescent probes for capturing endogenous hypochlorous acid in the lungs of mice.	Chemical Science	2018
30566855	Synthetic Oligonucleotides Inhibit CRISPR-Cpf1-Mediated Genome Editing.	Cell Reports	2018